Fox Chase Cancer Center News

Fox Chase Cancer Center and Arima Genomics, Inc., a company leveraging whole-genome sequence and structure information to provide comprehensive cancer therapy selection insights, today announced that they have entered into a new partnership to bring advanced diagnostics based on analysis of the three-dimensional structure of DNA into broad clinical practice.

New research reveals that the oncogene ERG initiates prostate cancer by reprogramming basal cells into luminal tumor cells, uncovering early vulnerabilities that could lead to more effective treatment and prevention strategies.

A new type of treatment called tumor-infiltrating lymphocyte (TIL) therapy is offering patients with melanoma more hope and another chance.

A Fox Chase Cancer Center study found that outpatient observation cut hospital stays dramatically, with no adverse safety events reported. It also freed up inpatient beds and cut healthcare costs.

A Fox Chase Cancer Center study found that measuring a patient’s absolute lymphocyte count can predict how well they’ll respond to the therapy for non-Hodgkin lymphoma. It could offer a practical tool for guiding treatment decisions.

Using the first-ever prostate cancer cell line from an Afro-Caribbean patient, investigators at Fox Chase Cancer Center and other members of the African Caribbean Cancer Consortium uncovered significant differences in how cancer drugs work across ancestries. These differences may help explain why, despite advances in treatment, Black men die from prostate cancer at twice the rate of White men.

For more than a decade, a class of drugs called spliceosome inhibitors has been studied as a strategy for killing cancer cells. Now, new research by Fox Chase Cancer Center scientists suggests that these drugs may be more effective as a tool to supercharge immunotherapy, drugs that harness the power of the body’s immune system, in small cell lung cancer.

Fox Chase Cancer Center’s Namrata ‘Neena’ Vijayvergia, MD, an expert in gastrointestinal cancers and rare neuroendocrine tumors, was recently recognized by two neuroendocrine tumor advocacy groups for her contributions to the field.